Intrathecal immunity in 37 patients seropositive for anti-HIV-1 antibody. 1988

J Reboul, and E Schuller, and G Pialoux, and M A Rey, and P Lebon, and F Brun-Vezinet
Laboratory of Neuro-Immunology, Hôpital de la Salpêtrière, Paris, France.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008297 Male Males
D002493 Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord. CNS Disease,Central Nervous System Disease,Central Nervous System Disorder,CNS Diseases,Central Nervous System Disorders
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated

Related Publications

J Reboul, and E Schuller, and G Pialoux, and M A Rey, and P Lebon, and F Brun-Vezinet
January 1988, Annals of the New York Academy of Sciences,
J Reboul, and E Schuller, and G Pialoux, and M A Rey, and P Lebon, and F Brun-Vezinet
February 1992, Proceedings of the National Academy of Sciences of the United States of America,
J Reboul, and E Schuller, and G Pialoux, and M A Rey, and P Lebon, and F Brun-Vezinet
March 1993, Lancet (London, England),
J Reboul, and E Schuller, and G Pialoux, and M A Rey, and P Lebon, and F Brun-Vezinet
June 1991, Journal of the American Academy of Dermatology,
J Reboul, and E Schuller, and G Pialoux, and M A Rey, and P Lebon, and F Brun-Vezinet
April 2014, The Journal of general virology,
J Reboul, and E Schuller, and G Pialoux, and M A Rey, and P Lebon, and F Brun-Vezinet
October 1994, Acta neurologica Scandinavica,
J Reboul, and E Schuller, and G Pialoux, and M A Rey, and P Lebon, and F Brun-Vezinet
December 2004, DNA and cell biology,
J Reboul, and E Schuller, and G Pialoux, and M A Rey, and P Lebon, and F Brun-Vezinet
April 1988, Lancet (London, England),
J Reboul, and E Schuller, and G Pialoux, and M A Rey, and P Lebon, and F Brun-Vezinet
September 1993, Nihon rinsho. Japanese journal of clinical medicine,
J Reboul, and E Schuller, and G Pialoux, and M A Rey, and P Lebon, and F Brun-Vezinet
January 1995, Bulletin of the New York Academy of Medicine,
Copied contents to your clipboard!